These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 9137386)

  • 1. [Treatment of myeloma: role of intensive treatments].
    Fermand JP; Ravaud P
    Presse Med; 1997 Apr; 26(11):521-4. PubMed ID: 9137386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High intensity regimens with autologous hematopoietic stem cell transplantation as treatment of multiple myeloma.
    Awedan AA
    Ann Transplant; 2002; 7(2):38-43. PubMed ID: 12416471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of multiple myeloma--melphalan monotherapy after bone marrow transplantation].
    Hájek R; Adam Z; Krejcí M; Vásová I; Král Z; Vorlícek J
    Vnitr Lek; 1996 Apr; 42(4):278-84. PubMed ID: 8693716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of multiple myeloma.
    San Miguel JF; Bladé Creixenti J; García-Sanz R
    Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
    Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
    Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Autologous transplantation of peripheral hematopoietic cells in a patient with multiple myeloma and renal insufficiency].
    Krejcí M; Doubek M; Adam Z; Hájek R; Vorlícek J; Mayer J
    Vnitr Lek; 1997 Nov; 43(11):756-8. PubMed ID: 9650509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose chemotherapy in multiple myeloma.
    Goldschmidt H; Hegenbart U; Wallmeier M; Moos M; Haas R
    Leukemia; 1997 Dec; 11 Suppl 5():S27-31. PubMed ID: 9436935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of high-dose chemotherapy in the treatment of multiple myeloma: a controversy.
    Kyle RA
    Ann Oncol; 2000; 11 Suppl 1():55-8. PubMed ID: 10707780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose chemotherapy and autologous stem cell transplantation in multiple myeloma: a single institution experience at All India Institute of Medical Sciences, New Delhi, using non-cryopreserved peripheral blood stem cells.
    Kayal S; Sharma A; Iqbal S; Tejomurtula T; Cyriac SL; Raina V
    Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):140-7. PubMed ID: 24342104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Value of hematopoietic stem cell autotransplantation in the treatment of multiple myeloma: initial experience at the National Bone Marrow Transplantation Center and review of the literature].
    Abdelkefi A; Ladeb S; Ben Othman T; Torjman L; Jeddi R; Ben Abdeladhim A
    Tunis Med; 2000 Oct; 78(10):548-56. PubMed ID: 11190737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of multiple myeloma by high dose chemotherapy, total body irradiation and autologous blood stem cell autograft.
    Fermand JP; Lévy Y; Gerota J; Benbunan M; Cosset JM; Castaigne S; Seligmann M; Brouet JC
    Nouv Rev Fr Hematol (1978); 1989; 31(2):85-7. PubMed ID: 2570400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
    Child JA; Morgan GJ; Davies FE; Owen RG; Bell SE; Hawkins K; Brown J; Drayson MT; Selby PJ;
    N Engl J Med; 2003 May; 348(19):1875-83. PubMed ID: 12736280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs.
    Martino M; Postorino M; Gallo GA; Messina G; Neri S; Piro E; Gentile M; Moscato T; Monteleone R; Fedele R; Mazzone C; Console G; Penna G; Alati C; Vincelli ID; Irrera G; Musolino C; Ronco F; Molica S; Morabito F
    Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):148-54. PubMed ID: 24417912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [High-dose melphalan in patients with multiple myeloma].
    Moreau P; Le Bonniec M; Harousseau JL
    Bull Cancer; 1999 Mar; 86(3):283-8. PubMed ID: 10210762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematopoietic stem cell autografts in support of myeloablative therapy for multiple myeloma.
    Barlogie B; Jagannath S; Vesole D; Tricot G
    J Hematother; 1994; 3(2):149-53. PubMed ID: 7922016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
    Kröger N; Perez-Simon JA; Myint H; Klingemann H; Shimoni A; Nagler A; Martino R; Alegre A; Tomas JF; Schwerdtfeger R; Kiehl M; Fauser A; Sayer HG; Leon A; Beyer J; Zabelina T; Ayuk F; San Miguel JF; Brand R; Zander AR
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):698-708. PubMed ID: 15389436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma.
    Reichardt VL; Okada CY; Stockerl-Goldstein KE; Bogen B; Levy R
    Biol Blood Marrow Transplant; 1997 Aug; 3(3):157-63. PubMed ID: 9310193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of relative anti-myeloma activity of high-dose melphalan followed by the first peripheral blood stem cell transplantation, as compared with the second transplantation, and to VAD chemotherapy.
    Awedan A; Król M; Blajer B; Rokicka M; Torosian T; Urbanowska E; Wiktor-Jedrzejczak W
    Transplant Proc; 2003 Sep; 35(6):2349-51. PubMed ID: 14529938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance therapy for remission in myeloma with Intron A following high-dose melphalan and either an autologous bone marrow transplantation or peripheral stem cell rescue.
    Powles R; Raje N; Cunningham D; Malpas J; Milan S; Horton C; Mehta J; Singhal S; Viner C; Treleaven J
    Stem Cells; 1995 Aug; 13 Suppl 2():114-7. PubMed ID: 8520498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phagocyte function decreases after high-dose treatment with melphalan and autologous stem cell transplantation in patients with multiple myeloma.
    Wichert S; Pettersson Å; Hellmark T; Johansson Å; Hansson M
    Exp Hematol; 2016 May; 44(5):342-351.e5. PubMed ID: 26774385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.